Get the Stockscreener App
1.60
0.00%
0.00
Hoth Therapeutics Inc stock is traded at $1.60, with a volume of 2.76M.
It is up +0.00% in the last 24 hours and up +25.98% over the past month.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
See More
Previous Close:
$1.60
Open:
$1.67
24h Volume:
2.76M
Relative Volume:
3.02
Market Cap:
$21.21M
Revenue:
-
Net Income/Loss:
$-7.51M
P/E Ratio:
-1.2121
EPS:
-1.32
Net Cash Flow:
$-8.02M
1W Performance:
+20.30%
1M Performance:
+25.98%
6M Performance:
+44.14%
1Y Performance:
+41.59%
1-Day Range:
$1.53
$1.70
1-Week Range:
$1.33
$1.80
52-Week Range:
$0.6506
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.60 | 21.35M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
Hoth Therapeutics climbs on $1 mln crypto reserve plan - TradingView
Hoth Therapeutics approved expansion of treasury reserve strategy to include Ethereum and Solana - MarketScreener
Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease - 富途牛牛
Hoth Therapeutics submits European application for skin toxicity drug - Investing.com
Hoth Therapeutics submits European application for skin toxicity drug By Investing.com - Investing.com UK
Hoth Therapeutics reaches EMA milestone for HT-001 phase II trial targeting EGFRi-linked skin toxicities - MarketScreener
Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities - PR Newswire
3 Under-the-Radar Biotechs Under $5 That Could Soar 200% - MarketBeat
Chart Analysts Warn of Resistance Near Hoth Therapeutics Inc. PriceJuly 2025 Market Mood & Capital Efficiency Focused Ideas - beatles.ru
How does Hoth Therapeutics Inc. correlate with NasdaqWeekly Trend Summary & High Win Rate Trade Tips - classian.co.kr
Earnings visualization tools for Hoth Therapeutics Inc.2025 Stock Rankings & Expert Approved Momentum Ideas - Newser
Can Hoth Therapeutics Inc. stock double in the next year2025 Earnings Impact & Stepwise Trade Signal Guides - خودرو بانک
Published on: 2025-09-06 01:25:14 - خودرو بانک
Hoth Therapeutics shares fall 2.24% premarket after adopting Lantern Pharma's AI-driven drug development tool. - AInvest
Is Hoth Therapeutics Inc. building a consolidation basePortfolio Profit Report & Weekly Hot Stock Watchlists - Newser
Is Hoth Therapeutics Inc. trending in predictive chart modelsPortfolio Update Summary & Reliable Intraday Trade Plans - Newser
Hoth Therapeutics adopts AI platform to advance drug development By Investing.com - Investing.com Canada
Is Hoth Therapeutics Inc. a momentum stockRate Cut & Risk Managed Investment Entry Signals - خودرو بانک
Hoth Therapeutics adopts AI platform to advance drug development - Investing.com India
Hoth Therapeutics shares fall 1.49% after-hours after adopting Lantern Pharma's AI-driven drug development tool. - AInvest
What indicators show strength in Hoth Therapeutics Inc.Dividend Hike & Real-Time Stock Movement Alerts - Newser
Lantern Pharma shares fall 1.52% intraday after FDA meeting and Hoth Therapeutics partnership. - AInvest
Using AI based signals to follow Hoth Therapeutics Inc.2025 Momentum Check & Free Community Consensus Stock Picks - Newser
AI-Driven Drug Development: Hoth Therapeutics and Lantern Pharma’s Strategic Partnership to Revolutionize CNS Therapies - AInvest
Lantern Pharma's PredictBBB.ai Platform to Drive Next-Gen Drug Development with Hoth Therapeutics Partnership - AInvest
Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development - WV News
Is Hoth Therapeutics Inc. benefiting from innovation trendsWeekly Profit Analysis & Smart Investment Allocation Tips - خودرو بانک
Exit strategy if you’re trapped in Hoth Therapeutics Inc.Market Activity Recap & Proven Capital Preservation Tips - Newser
Why Hoth Therapeutics Inc. is moving todayMarket Activity Summary & Daily Stock Momentum Reports - Newser
How to build a custom watchlist for Hoth Therapeutics Inc.Earnings Overview Summary & Long-Term Safe Investment Plans - Newser
Hoth Therapeutics Inc. stock daily chart insightsJuly 2025 Snapshot & Safe Capital Allocation Plans - Newser
Is Hoth Therapeutics Inc. stock poised for growthExit Point & Reliable Price Breakout Alerts - Newser
Will Hoth Therapeutics Inc. announce a stock splitAnalyst Upgrade & Weekly Top Stock Performers List - خودرو بانک
Forecasting Hoth Therapeutics Inc. price range with options dataOptions Play & Step-by-Step Trade Execution Guides - Newser
Has Hoth Therapeutics Inc. found a price floorGold Moves & Precise Entry and Exit Recommendations - Newser
Hoth Therapeutics Inc. stock trend outlook and recovery pathVolume Spike & Free Daily Entry Point Trade Alerts - Newser
Real time breakdown of Hoth Therapeutics Inc. stock performanceMarket Risk Analysis & Free Low Drawdown Momentum Trade Ideas - Newser
What momentum shifts mean for Hoth Therapeutics Inc.Insider Buying & Reliable Momentum Entry Alerts - Newser
How to escape a deep drawdown in Hoth Therapeutics Inc.Market Rally & High Yield Equity Trading Tips - Newser
Using R and stats models for Hoth Therapeutics Inc. forecastingQuarterly Portfolio Report & Smart Swing Trading Techniques - Newser
Published on: 2025-09-03 06:36:55 - Newser
Applying Elliott Wave Theory to Hoth Therapeutics Inc2025 Volume Leaders & Daily Risk Controlled Trade Plans - Newser
Hoth Therapeutics Plunges 10.94% Amid Market Volatility - AInvest
Understanding Hoth Therapeutics Inc.’s price movementEntry Point & Fast Moving Market Watchlists - Newser
How to track smart money flows in Hoth Therapeutics Inc.2025 Geopolitical Influence & Real-Time Chart Pattern Alerts - Newser
Hoth Therapeutics Inc. stock prediction for this weekJuly 2025 Volume & AI Driven Stock Reports - Newser
Applying Elliott Wave Theory to Hoth Therapeutics Inc.Weekly Gains Summary & Daily Stock Trend Watchlist - Newser
Multi asset correlation models including Hoth Therapeutics Inc.July 2025 Selloffs & Smart Investment Allocation Insights - Newser
Hoth Therapeutics stock soars on positive preclinical data for cancer drug By Investing.com - Investing.com South Africa
Is Hoth Therapeutics Inc. a potential multi baggerJuly 2025 Opening Moves & Weekly High Return Opportunities - خودرو بانک
Hoth Therapeutics stock soars on positive preclinical data for cancer drug - Investing.com Nigeria
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):